Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: Novel insights into pathophysiology and emerging opportunities for treatment

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 749-753

  Magkos, Faidon ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; EDITORIAL; FATTY ACID BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADIPONECTIN; ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; GLYCEROL; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; LIPOLYSIS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 79956126364     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.09.011     Document Type: Editorial

References (45)

1. Lugassy DM, Farmer BM, Nelson LS. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART). Emerg Med Clin North Am 2010;28:409-19.
2. Leow MK, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961-76. (Pubitemid 36549862)
3. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62. (Pubitemid 40075680)
4. Calmy A, Hirschel B, Cooper DA, et al. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007;370:12-4. (Pubitemid 47017451)
5. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802. (Pubitemid 36337987)
6. Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 2009;94:1089-91.
7. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006;41:453-60.
8. Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003;32:482-9. (Pubitemid 36423118)
9. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-72.
10. Dimock D, Thomas V, Cushing A, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism 2010.
11. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008;122:e129-e138.
12. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-9. (Pubitemid 36549708)
13. Calmy A, Carey D, Mallon PW, et al. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med 2008;9:101-10.
14. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual x-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45:508-14. (Pubitemid 47294922)
15. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6. (Pubitemid 30437589)
16. Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis.'. Curr Opin Lipidol 2004;15:59-67.
17. Hadigan C, Borgonha S, Rabe J, et al. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002;51:1143-7.
18. Reeds DN, Yarasheski KE, Fontana L, et al. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 2006;290:E47-E53.
19. Adler-Wailes DC, Guiney EL, Wolins NE, et al. Long-term ritonavir exposure increases fatty acid and glycerol recycling in 3T3-L1 adipocytes as compensatory mechanisms for increased triacylglycerol hydrolysis. Endocrinology 2010;151:2097-105.
20. Carpentier A, Patterson BW, Uffelman KD, et al. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005;178:165-72. (Pubitemid 39600829)
21. Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIVlipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002;283:E332-E337.
22. Sekhar RV, Jahoor F, Pownall HJ, et al. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005;81:1405-10. (Pubitemid 41710245)
23. Reeds DN, Mittendorfer B, Patterson BW, et al. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003;285:E490-E497. (Pubitemid 37010825)
24. Stein JH, Merwood MA, Bellehumeur JB, et al. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol 2005;25:399-405. (Pubitemid 40189164)
25. Seip RL, Semenkovich CF. Skeletal muscle lipoprotein lipase: molecular regulation and physiological effects in relation to exercise. Exerc Sport Sci Rev 1998;26:191-218. (Pubitemid 128461557)
26. den Boer MA, Berbee JF, Reiss P, et al. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 2006;26:124-9. (Pubitemid 43732238)
27. Deveaud C, Beauvoit B, Reynaud A, et al. Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3′-azido-3′- deoxythymidine-treated rats. Antimicrob Agents Chemother 2007;51:583-90. (Pubitemid 46185276)
28. Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003;362:1758-60. (Pubitemid 37468330)
29. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010;375:2267-77.
30. Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605-11. (Pubitemid 44024625)
31. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-44.
32. Rao MN, Mulligan K, Tai V, et al. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010;95:4361-6.
33. Sutinen J. The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res 2009:373524.
34. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 2010;11:39-50.
35. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010;10:183.
36. Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010;91:267S-72S.
37. Sekhar RV, Patel SG, D'Amico S, et al. Effects of rosiglitazone on abnormal lipid kinetics in HIV associated dyslipidemic lipodystrophy: a stable isotope study. Metabolism 2010.
38. Kalderon B, Mayorek N, Ben-Yaacov L, et al. Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo. Am J Physiol Endocrinol Metab 2003;284:E795-E803. (Pubitemid 36323874)
39. Liu LF, Purushotham A, Wendel AA, et al. Regulation of adipose triglyceride lipase by rosiglitazone. Diabetes Obes Metab 2009;11:131-42.
40. Hadigan C, Rabe J, Meininger G, et al. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003;77:490-4. (Pubitemid 36133394)
41. Lindegaard B, Frosig C, Petersen AM, et al. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy. Diabetes 2007;56:2070-7. (Pubitemid 47195819)
42. HadiganC, Liebau J, TorrianiM, et al. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 2006;91:4438-44.
43. Chow DC, Tasaki A, Ono J, et al. Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome. Biologics 2008;2:917-21.
44. Mantzoros CS, Li T, Manson JE, et al. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-8. (Pubitemid 41159340)
45. Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 2010.